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Abstract
Introduction: Non-Alcoholic Fatty Liver Disease (NAFLD) is the most common
chronic liver disease in children and adults, outpacing alcoholic and viral liver
disease in recent years. NAFLD has been linked to obesity, diabetes and the
metabolic syndrome (MetS). Adverse health outcomes include cardiovascular
disease, liver cirrhosis, and liver cancer. Prevalence of NAFLD is increasing in all
ages but reasons remain unclear.
Aim: To determine which individual MetS components and related disturbances
(e.g., elevated uric acid and insulin resistance) are linked to NAFLD, and if these
relationships varied by age (adolescents vs adults).
Methods: Data from the National Health and Nutrition Examination Survey
(NHANES) collected in 2001-2006 (n=12,248) were analyzed. Outcome variable
was >30 u/L of the liver enzyme aminotransferase (ALT), a surrogate marker of
NAFLD in lieu of the Gold Standard liver biopsy or imaging. Independent variables
were: five MetS components and other NAFLD-related risk factors. We conducted
multivariate Binary Logistic Regression of these study variables adjusted for
education level, race, age, sex, and physical activity.
Results: In adults (20+ years), high uric acid was associated with a three-fold
likelihood of having NAFLD (OR=3.64, 95% CI 2.89-4.59). Compared to
participants with a college degree, those who completed some college or some
high school had higher risks of NAFLD (OR=1.32 95% CI 1.03-1.69; OR=1.33,
95% CI 1.01-1.68; respectively). In adolescents (12-19 years), high uric acid also
was associated with NAFLD (OR=3.46, 95% CI 2.48-4.83) as were black
vii

adolescents (OR=1.20, 95% CI 1.003-1.44). For all ages, MetS individual
components were not significantly associated with NAFLD nor was physical
inactivity, or obesity.
Conclusion: Our study adds novel population-based evidence that social factors
were associated with NAFLD. Specifically, NAFLD was relatively more prominent
in black adolescents and, in adults, with less than a college degree. The three-fold
greater prevalence of elevated uric acid in both age groups warrants further
research and might have translational value for screening for liver disease.
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INTRODUCTION
Overview. Nonalcoholic fatty liver disease is considered the hepatic component
of the metabolic syndrome even though it is not yet part of the clinical definition.
The concept of this form of liver disease was first introduced in 1980 when a group
of physicians in Mayo clinic described biopsy findings of 20 patients that mimic
alcoholic hepatitis, however, the cause was unknown. Histological findings ranged
from fatty infiltrates in liver cells, to inflammation and necrosis in the lobules, to
frank cirrhosis in a few patients. Most of these patients were obese and many had
diabetes or gall bladder stones (Ludwig, 1980).
Nonalcoholic fatty liver disease (NAFLD) is divided into two histological forms; the
simple form is nonalcoholic fatty liver (NAFL) in which fat accumulates in liver cells
without evidence of liver cell injury and inflammation, and the more severe form is
nonalcoholic steatohepatitis (NASH) where fat accumulation is accompanied by
liver cell injury and inflammation in the form of cell ballooning with or without
fibrosis. Gold standard diagnosis of NAFLD is by histology, liver imaging is also a
good diagnostic tool, both need the exclusion of other causes of liver steatosis,
including significant alcohol consumption, viral hepatitis, hereditary disorders and
certain medications. NAFLD has been linked to metabolic risk factors, including
diabetes, obesity, lipid disorders and metabolic syndrome. The most common
cause of death in patients with NAFLD is cardiovascular disease, patients with
NASH particularly have an increased risk of liver-related mortality due to cirrhosis
and liver cancer (Chalasani, 2012).

1

Liver enzymes Alanine Aminotransferase (ALT) and Aspartate Aminotransferase
(AST) could be elevated in people with NAFLD. Even though they could be normal,
they are still the most common cause of referral to the gastroenterologists and
NAFLD remains the most common cause of elevated liver enzymes. Evidence
showed that elevated liver enzymes in the presence of NAFLD is a risk factor for
developing end-stage liver disease (Ekstedt, 2006). Liver enzymes are also
correlated with metabolic syndrome and its components in people with NAFLD, a
study in China found that persons with ultrasound-diagnosed NAFLD were more
likely to have metabolic syndrome if they have high levels of ALT (Chen, 2007).
While NAFLD is associated with metabolic syndrome in adults, adolescents, and
children, population-based evidence is lacking on the relationship between
elevated liver enzymes and the specific metabolic syndrome components, which
could have implications for possible differences in causal etiology in adults versus
younger patients. Similarly, also lacking are high-quality data on other potential
correlates of NAFLD such as systemic inflammation (e.g., C-Reactive Protein),
smoking status, physical inactivity, and other possible risk factors, and, if the
relationships also differ by age group. The following sections describe these issues
in more detail as the foundation of this research project.

Epidemiology. Since imaging doesn’t recognize NAFL from NASH, and given the
invasiveness of biopsy as a procedure, that renders the prevalence of NAFLD hard
to determine. Back in 1990, an autopsy study of 351 nonalcoholic patients found
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NAFLD changes in 18.5% of the obese and 2.7% of the lean patients (Wanless
and Lentz, 1990).
In the general population worldwide, and with using different criteria for
determining people with NAFLD, research showed that the condition is prevalent
and is associated with obesity and insulin resistance (Lazo, 2008). In the
participants of the Dallas Heart Study in the United States the prevalence was 31%
by measuring fat content of the liver (Browning, 2004). Lazo and colleagues found
the prevalence of NAFLD to be around 20% using liver ultrasonography in
participants 20-74 years old of NHANES III (Lazo, 2013). A study used 70 living
liver donors found steatosis in 38.5% of the participants, which was the most
common histological finding (Tram, 2005). The prevalence was found to be higher
in high risk groups, it reached 90% in obese patients (Machado, 2006) and 69% in
diabetics (Leite, 2008).
For epidemiological research, it is neither ethical nor practical to perform a liver
biopsy for each suspected case of NAFLD, liver enzymes have been used as
surrogate markers (Clark, 2003). Several studies aimed to assess the prevalence
and extent of NAFLD using liver enzymes as surrogates. Clark and colleagues
studied liver enzymes in participants 17 and older in the third NHANES 1988-1994,
the cutoff points for elevated liver enzymes were AST > 37 U/L or ALT >40 U/L in
men, and AST or ALT >31 U/L in women. The prevalence of elevated
aminotransferases (AST, ALT, or both) was 7.9%, 69% of these elevations were
not explained by viral hepatitis or significant alcohol consumption. They also found
that men and women with unexplained elevations were more likely to have higher
3

BMI, waist circumference, triglycerides (TG) and insulin, they also were more likely
to have type 2 diabetes and lower high density lipoprotein (HDL) (Clark, Frederick,
Brancati & Diehl, 2003).
Ioannoua and colleagues conducted a similar study using the continuous NHANES
1999-2002 their cutoff values for elevated liver enzymes were AST >40 and ALT
> 43 in men and women. The prevalence of elevated ALT, AST or both were 8.9%,
4.9% and 9.8%, high ALT in NHANES 1999-2002 was more than double that in
NHANES III using the same cutoff values. Elevated ALT was associated with male
gender, Mexican American ethnicity, higher BMI, hepatitis C virus (HCV) antibody
and alcohol consumption. Even after excluding HCV and significant alcohol
consumption, the prevalence of high ALT was still high (7.3%) and associated with
risk factors for NAFLD (Ioannou, 2006).

Link with the metabolic syndrome. Ioannou also found in NHAES III that
metabolic syndrome was associated with increased ALT (OR 3.3, CI, 1.4-8.0), as
well as obesity and insulin resistance (Ioannou, 2005). In another NHANES III
study he found that participants with elevated ALT without viral hepatitis or
excessive alcohol consumption had a higher Framingham Risk Score (FRS) of
CHD (Ioannou, Weiss, Boyko, Mozaffarin &Lee, 2006)
In a nested case control study using NHNAES III to assess the relationship
between unexplained elevations in ALT and metabolic syndrome, researchers
found that the prevalence of elevated ALT in people with metabolic syndrome was
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double that in those without it (OR 2.07, CI, 1.78-2.41) (Liangpunsakul &Chalsani,
2005).
The metabolic syndrome is defined by the NCEP: ATPIII as having three or more
of the following: central obesity: waist circumference of greater than 102 cm in
males and greater than 88 cm in females, hypertriglyceridemia: triglycerides level
of 150mg/dL or greater, low HDL: less than 40 mg/dL in males and less than 50
mg/dL in females, hypertension: blood pressure of 135/85 or higher and fasting
blood glucose of 110 mg/dL or higher (Expert panel on detection, evaluation, and
treatment of high blood cholesterol in adults, 2001). The International Diabetes
Federation (IDF) and the American Heart Association/ National Heart, Lung, and
Blood Association (AHA/NHLBI) agreed in the Joint Scientific Statement to
harmonize the definition of metabolic syndrome in 2009. The criteria are:
triglyceride level of 150mg/dL or greater or drug treatment for elevated
triglycerides, HDL level of less than 40 mg/dL in men or less than 50 mg/dL in
women or drug treatment for low HDL, systolic blood pressure greater than 135
mm Hg and/or diastolic blood pressure greater than 85 mm Hg or drug treatment
for hypertension, fasting blood glucose of 100 mg/dL or higher or drug treatment
for diabetes, waist circumference has population- and country- specific definitions
(Alberti et al., 2015). Currently, the ATP III and The AHA are the two most widely
used definitions.

Health outcomes. Liver steatosis alone without inflammation (NAFL) was thought
to be non- progressive, the more severe form, NASH, has been linked to liver

5

cancer with or without cirrhosis (Fazel, 2016). Research attempted to better
understand the natural history of NAFLD. A study in Sweden followed patients with
biopsy-proven NAFLD for a mean of 13.7 years found that NASH rather than NAFL
was more associated with reduced survival, the most common cause of death was
cardiovascular events, followed by liver-related causes (Ekstedt, 2006). A more
recent smaller study in France with a shorter duration showed that NAFL can
progress to NASH, especially in the presence of metabolic risk factors (Pais,
2013). In the United States, a group of researchers conducted a cohort study using
the Rochester Epidemiology Project in Minnesota, patients diagnosed with NAFLD
by imaging or histology between 1980 and 2000 were identified and their survival
was analyzed. Results showed increased mortality compared to general
Minnesota population, the leading cause was liver-related mortality and
associations were age, impaired fasting glucose and liver cirrhosis (Adams, 2005).
Hepatocellular carcinoma (HCC) is the most common primary liver cancer in the
united states, it is the 5th most common cancer and the third leading cause of
cancer death. risk factors include viral hepatitis and alcoholic cirrhosis (Mittal and
El-Seraj, 2013). Research also showed that obesity (Marengo, 2016), diabetes
(Davila, 2005) and metabolic syndrome (Welzel, 2011) are additional risk factors
and are increasing in the United States (Flegal, 2010) and (Cowie, 2006). HCC in
also increasing in the United States as was shown by a study using Surveillance,
Epidemiology and End Results (SEER) registries from 1975-2005, the incidence
tripled and the 1-year survival remains less than 50% (Altekruse, 2009). NAFLD
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has been also linked to HCC (Ascha, 2010) and (Mittal et.al, 2015), even in the
absence of cirrhosis (Perumpail, 2015) and (Pocha, 2015).

Intervention. Treatment of NAFLD includes treating the liver disease itself in
addition to the associated obesity, hyperlipidemia and diabetes. The mainstay of
treatment is lifestyle modification. A randomized controlled trial found that low
calorie diet and exercise improved liver histology, even without weight loss
(Eckard, 2013). Another study emphasized weight loss in diabetics to reduce liver
fat content (Peterson, 2005). Bariatric surgery has been also found to improve
histological features of NAFLD (Taitano, 2014). Other treatments include insulin
sensitizers like pioglitazone and antioxidants like vitamin E. pioglitazone reduces
insulin resistance, while Vitamin E improves histology of NAFLD and reduces liver
enzymes levels (Sanyal, 2010).

Pediatric NAFLD. NAFLD is also prevalent in children and adolescents in the
United States, it is the leading cause of liver disease in children. The disease in
children resembles the adult form with differences in the details of fibrosis and
inflammation in NASH patients. The diagnosis also needs liver imaging or
histological examination. Pediatric NAFLD parallels the rise in obesity rates in
children (Loomba, 2010).
A study that examined natural history of NAFLD in children showed association
with metabolic syndrome components. It also showed disease progression to
fibrosis and even cirrhosis, and decreased survival in comparison with the general
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population (Feldstein, 2009). A liver transplant study showed that NASH in
childhood can progress to end-stage liver disease and it can recur in the
transplanted liver (Alkhouri, 2016). The associated morbidities are cardiovascular,
metabolic syndrome components, type 2 diabetes and low bone mineral density
which leads to increased risk of fractures (Nidhi, 2016).
To estimate the prevalence of NAFLD in children and adolescents, an autopsy
study found it to be 9.6% in children between 2-19 year- old and reached up to
17.3% in 15-19-year-old, it was the most common liver abnormality and reached
38% in obese children (Schwimmer, 2006). Studies using the continuous NHANES
used liver enzymes as surrogates of NAFLD, one (NHANES 1999-2004) found that
8% of adolescents 12-19 years old have NAFLD, the prevalence was higher in
Mexican American (11.5%) and lower in black (6%) (Fraser, 2008). Another study
found that the prevalence rose from 3.9% in NHANES III to 10.7% in the
continuous NHANES 2007-2010 in adolescents 12-19 years old. The criteria used
for NAFLD were overweight and high ALT, with the exclusion of hepatotoxic
medications and chronic hepatitis (Welsh, 2013).
Treatment of pediatric NAFLD with increasing physical activity and tailoring diet to
the patient’s individual needs showed improvement in liver histology and liver
enzymes in children 5-18 years old (Nobili, 2008). Antioxidants and metformin
have not been found to be more effective than placebo (Lavine, 2010).
In children and adolescents, metabolic syndrome has a modified definition of the
ATP III criteria; literature defined it as having three of the following five criteria:
triglycerides of 110 mg/dL or more, HDL of 40 or less, waist circumference on the
8

90th or above percentile for age/gender, blood glucose of 100 mg/dL or more, and
blood pressure on the 90th or above percentile for age, height and gender.
In NHANES 1999-2010, the prevalence of metabolic syndrome in 12-19-year-old
was 10.6% in Hispanics, 8.4% in whites and 4.2% in blacks. The prevalence of
high ALT >30 U/L parallels the prevalence of metabolic syndrome: 13.7% in
Hispanics, 8.6% in Whites and 5.2% in blacks. adolescents with metabolic
syndrome were 7.8 times more likely to have elevated ALT (DeBoer et al., 2013).

Specific aims of the study. While NAFLD is associated with metabolic syndrome
in adults and children, this study wants to explore the relationship between
metabolic syndrome components and elevated ALT in adolescents and adults, in
addition to other risk factors, including C-Reactive protein (CRP), uric acid, lifestyle
factors like smoking and exercise, and education as an indicator of socioeconomic
status and their association with elevated liver enzymes. High uric acid levels
(higher than 7) has been shown to be associated with elevated liver enzymes and
NAFLD in adults. Insulin resistance can lead to reduced excretion of uric acid
through the kidneys which causes elevated levels in the blood (shih, 2012). This
association in adolescents will be examined in our study, it is expected that uric
acid will be associated with liver enzymes. High ALT level is expected to be
associated with metabolic syndrome components, lower levels of exercise and
lower education. The degree of association in adults and children are compared
together.
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METHODS
Sample. The NHANES is a large, ongoing population-based surveillance program
conducted by the National Center for Health Statistics (NCHC), a part of the
Centers for Disease Control and Prevention (CDC) it started in early 1960s as a
series of surveys and became a continuous study in 1999. The survey is a
combination of questionnaire, interview, medical examination at home and in a
mobile center and Laboratory tests. Data from NHANES provides information
about nutrition, infection, and environmental and chronic health conditions in the
United States. The survey uses a multistage probability sampling of the civilian
non-institutionalized population of the United States of all ages. Detailed
description of the sampling method and the survey could be found in the CDC
website at the link: http://www.cdc.gov/nchc/nhanes/about_nhanes.htm. Our study
sample (n=12,448) consists of males and non-pregnant females in NHANES 20012006 ages 12 and older with valid ALT results; n=2,257 with high ALT values and
n=10,191 with normal ALT.
Variables. ALT was used as a surrogate marker for NAFLD (dependent variable).
ALT is more closely related to liver fat than other liver enzymes (Schindhelm,
2005). In our study, it was dichotomized into normal (30 U/L and lower) and
elevated (over 30 U/L) in both children and adults. The cutoff point was used
previously (DeBoer, 2013) and was the 97th percentile in NHANES III (Strauss,
2000). Several independent variables were examined in the study. Demographic
characteristics including age, sex, race, and education. Metabolic syndrome
components based on the definition by the Joint Scientific statement in adults 20
10

and older and the modified definition in 12-19-year-old participants. Body Mass
Index (BMI) which is weight in kilograms divided by the squared height in meters.
In adults, BMI was categorized as normal if it was between 18.5 and 24.9,
overweight between 25-29.9, and obese if it was 30 or greater. In 12-19 age group,
BMI was categorized as normal if it was under the 85th percentile for age,
overweight is between the 85th and the 95th percentiles and obese above the 95th
percentile. Smoking status was classified into three categories: never, previous
and current in adults 20 and older.
C-reactive protein (CRP) is an inflammatory marker and has been linked to colon
cancer and cardiovascular disease. The CDC/ American Heart Association
workshop classified CRP as low risk for cardiovascular disease if it is less than1
mg/L, average risk between 1 and 3, and high risk above 3 mg/L (Roberts, 2004).
In our study, we classified it as normal (3 or less) and high (higher than 3).
Homeostasis Model Assessment method (HOMA) was calculated using the
formula: (Fasting Insulin(uU/ml) *Fasting glucose(mmol/L)/22.5), HOMA-IR with a
score of 3.6 (the 75th percentile in our study) or higher indicates insulin resistance.
Uric acid has been also linked with coronary heart disease. Hyperuricemia, or high
uric acid, was categorized into normal (7mg/dL or less) or high (greater than 7
mg/dL). Physical activity was classified based on meeting the American College of
Sports Medicine (ACSM) recommendations for daily exercise as no exercise,
below, or meeting ACSM recommendations. Physical activity was assessed by
self-report in the last 30 days (Garber, 2011).
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Metabolic syndrome components were classified into normal or high based on the
Joint Scientific Statement definition. In 12-19 age group, waist circumference was
divided by height in centimeters to get a waist circumference/height ratio (WHR),
a variable that has been found to be associated with high ALT in Japanese
Children (Ochiai, 2015) and with higher blood pressure in Chinese children (Zhang,
2017). WHR has increased over time in United States children 2-19 years old (Li,
2006). In our study, it was categorized into normal and elevated with the cut point
of (0.66) which was the 90th percentile.
Statistical analysis was done using Statistical package or Social Sciences (SPSS)
software version 24. Chi square test was used to examine the prevalence of
independent variables and compare them between the two groups of high versus
normal ALT. Logistic regression was used to find variables that predict high ALT.
statistical significance was defined as P value of 0.05 or less.
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RESULTS
Demographic characteristics of our study population are shown in Table 1. The
overall prevalence of elevated ALT (i.e., surrogate for liver disease) was 18.1%
(2257/12,448). The prevalence of high ALT varied somewhat across age groups
and approached significance (16.3% to 19%, p=0.055). Prevalence also differed
by race/ethnic group (p=0.063): 18.2% for Mexican American/other Hispanics,
17.3% in Non-Hispanic Whites, and 19.4% in Non-Hispanic Blacks. Prevalence did
not differ by sex (males, 18.3%; females, 17.7%; p=n.s). Elevated ALT rate varied
somewhat by education group but no clear pattern emerged (p= 0.052).
Tables 2a through 2e stratify our study population by age category to compare
prevalence of elevated ALT. Uric acid was elevated among all those with NAFLD
in each age group, ranging from 19.8% (12-19 yrs) to 24.2% (80 yrs and older) in
a stepwise manner. Insulin resistance, as measured by the Homeostatic Model
Assessment (HOMA-IR), was observed to be present in proportionally lower rates
among participants with NAFLD compared to healthy participants in age groups
40-59 (18.3% vs 27.8%, p=0.003), and 60-79 (20.7% vs 32.7%, p=0.007). The
same pattern was observed in participants 80 yrs old and higher but this difference
did not reach statistical significance.
Table 3a describes metabolic syndrome components in 12-19 yr age group
participants using the modified ATP III definition, and measuring waist
circumference/height ratio instead of waist circumference alone. Persons with high
ALT did not significantly differ from those with normal ALT with respect to the
presence or absence of individual components. Tables 3b and 3c describe
13

metabolic syndrome components in males and females, respectively, in the age
group of 20 years and older in relation to ALT level. The only statistically significant
difference (p=0.007) was, unexpectedly, that 49.3% of healthy males had elevated
fasting blood glucose compared to 41.9% in males with elevated ALT level.
Table 4 shows results of a logistic regression model where age, sex, race/ethnicity,
physical activity and BMI were fit as predictors of high ALT for 12-19-year-olds.
Black participants were 1.2 times more likely to have high ALT than Mexican/Other
Hispanic (95% CI 1.003-1.437) controlling for sex, physical activity or BMI. Age
was also inversely associated with high ALT level with odds ratio of 0.964 (CI
0.932-0.998) per one year of age. We also performed logistic regression in this
age group to determine which components of Metabolic Syndrome as well uric acid
and the HOMA-IR might predict elevated ALT. children with elevated uric acid level
(i.e., > 7 mg/dL) had 3.46 times the risk (95% CI 2.48-4.83) of having high ALT
compared to children with normal levels.
For adults ages 20 and older, a regression model was fit to examine predictors of
high ALT (Table 6), which showed that, compared to people with college
education, those with less than ninth grade education were 1.316 times more likely
to have high ALT (95% CI 1.026-1.689). Likewise, people who finished high school
were 1.33 times (CI 1.005-1.675) more likely to have high ALT than those with
college degrees. As with the younger age group, elevated uric acid was a
significant predictor of elevated ALT (OR=3.8 95% CI 2.97-4.87) in the 20 yrs and
older group (Table 7). Insulin resistance was significant with p value 0.014, people
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with HOMA of less than 3.6 were less likely to have high ALT than those with
HOMA 3.6 or greater (OR 0.71, CI: 0.54-0.93).
DISCUSSION

Prevalence of NAFLD. The prevalence of elevated ALT in our study was 18.1%
in the total population, which, surprisingly, did not vary substantially by age group,
race/ethnicity or sex. Prior studies using the continuous NHANES found the
prevalence to be lower than our study in adults and children but these studies of
adults used higher cut points. (Clark, Frederick, Brancati & Diehl, 2003; & Ioannou,
2006). The prevalence rate in our study, however, is consistent with prevalence of
NAFLD using better diagnostic tools like imaging (Lazo, 2013), and autopsy
studies in children (Schwimmer, 2006).

Metabolic Syndrome and NAFLD. We did not find any significant association
between specific metabolic syndrome components and high ALT, while prior
studies using NHANES III found that the risk of having high ALT in people with
metabolic syndrome was double that risk in people who did not have metabolic
syndrome (Liangpunsakul &Chalsani, 2005). We did not use metabolic syndrome
as a whole entity, however, as we wanted to explore individual components as
predictors of NAFLD. In multivariate logistic regression, our study did not produce
evidence of a relationship between elevated HOMA-IR (i.e., insulin resistance) with
elevated ALT in either age group. It is possible that the age group of ≥20 years is
a broad of a risk group, and we will analyze narrower age groups prior to
submission of this study for publication.
15

On the other hand, metabolic syndrome has been shown to have low sensitivity to
detect insulin resistance in adolescents (Deboer and Gurka, 2014) which might
explain the lack of association of metabolic syndrome individual components with
high ALT in our study in the young age group. The lack of an association between
insulin resistance (i.e., elevated HOMA-IR) and ALT in those older than age 20 is
puzzling for biologic reasons. Insulin resistance explains NAFLD physiologically in
basic science by the release of free fatty acids from the insulin resistant fat tissue
and because of imbalance between lipid excretion and uptake by the liver cells,
this leads to fat accumulation in the liver cells and, when inflammation is present,
to NAFLD and NASH (Dietrich & Hellerbrand, 2014).
Another diagnostic marker of metabolic syndrome is elevated waist circumference
which reflects central obesity, but we did not see associations with this condition
and elevated ALT in either age group. Central obesity is characterized by
accumulation of both subcutaneous and visceral fat. While in adults central
adiposity is part of the definition of the metabolic syndrome, in children, the
modified definition of metabolic syndrome includes waist circumference that is at
the 90th percentile for age and sex (Deboer, 2013), Waist/height ratio is believed
to be a better measure of central obesity in children and adolescents since it
considers growth in both height and waist circumference, it is also valid for males
and females without the need for separating values for each sex (Li, 2006).
Waist/height ratio in our study was not significant in predicting ALT in the age group
12-19 using more than one cut point.
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Elevated Uric Acid and NAFLD. High uric acid was significantly associated with
high ALT in all age groups, independent of metabolic syndrome components. A
study of NHANES III participants ages 20-74 found that ultrasound -diagnosed
NAFLD was significantly higher in people with higher uric acid levels, also, people
with hyperuricemia were 1.4 times more likely to have NAFLD. Hyperuricemia was
also significantly associated with elevated ALT. It is not known if the high uric acid
is a cause or a consequence of NAFLD, however, a prospective Chinese study
found after 3 year-follow up that people with higher basic levels of uric acid were
more likely to develop NAFLD (Xu, 2010). An article hypothesized that fructose
plays a role in NAFLD and metabolic syndrome (Lim, 2010). Our study extends the
association between uric acid and ALT to children 12-19.

Demographic characteristics and NAFLD. We did observe, however, that
African-Americans were at higher risk for elevated ALT among those under 20
years but, that in the older age group, education was inversely associated with
elevated ALT. To the best of our knowledge, our study is the first to find an
increased risk of high ALT as a marker of NAFLD in black adolescents. Prior
reports have shown a lower prevalence of reported lower prevalence of NAFLD
(and metabolic syndrome) in Blacks of all ages. (Beltran-Sanchez, 2011; Ioannou,
2006; Deboer, 2013; & welsh, 2013). With respect to education, a Chinese study
found a relationship between SES and NAFLD in patients hospitalized with type 2
diabetes mellitus (Jia, 2015), patients in the lower SES were more likely to develop
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NAFLD, had higher BMI, higher insulin resistance, and poorer general, emotional
and mental health.
Strengths and Limitations. Our study was conducted on a large, nationally
representative sample of civil non-institutionalized men, nonpregnant women and
children 12-19 in the United States consisting of validated data. However, there
are several limitations, most notably, the cross-sectional nature of the study shows
does not permit causal inference. Causality, of course, helps direct prevention and
targeted screening.
Also, we did not exclude participants with excessive alcohol use, a prominent risk
factor of liver disease, due to a high level of missing data. Scientifically, we can
justify this lack of exclusion based on findings from a large, longitudinal study that
followed middle aged men and women without metabolic syndrome for average of
6.4 years, at the end of the follow up, people with high ALT were 2.25 times more
likely to develop metabolic syndrome regardless of age, sex, or alcohol intake
(Schindhelm, 2007). Further, NAFLD now reflects the vast majority of chronic liver
diseases, rising from 46.8% of all cases in 1988 to 75.1% in 2008 (Younossi,
2011).
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Conclusion

In a nationally representative cross-sectional study of US adolescents (12-19 yrs)
and adults (≥20 yrs), we found that elevated uric acid was associated with a threefold likelihood of NAFLD in both age groups controlling for individual components
of the metabolic syndrome. With respect to demographic characteristics, we
observed that, in adolescents, African Americans had a significantly higher risk of
NAFLD, but, for adults, education was inversely related to NAFLD. Unexpectedly,
insulin resistance, as measured by elevated HOMA-IR, was inversely linked to
NAFLD in both age groups whereas no other components of the metabolic
syndrome were associated with liver disease.
Our finding concerning high uric acid is consistent with an imaging-based national
study with proven NAFLD in NAHNES III participants (Sirota et al., 2013). Since
having high liver enzymes is the most common cause of referral to the
gastroenterologists, these risk factors could help guide clinicians to develop
screening protocols for their patients. NAFLD can lead to advanced liver disease
and other sequelae like diabetes and cardiovascular disease in all ages. It is for
these reasons that NAFLD has been described in the literature as a component of
metabolic syndrome although it has not yet been officially included in the clinical
definition. Of note, metabolic syndrome, when introduced by a Swedish physician
over 80 years ago, included high uric acid as one of the characteristics (Pais,
2009). Based on the significant association between uric acid and high liver
enzymes in our study, and the significant association between insulin resistance
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and NAFLD, obesity and metabolic syndrome in many other studies to date, the
value of high uric acid triggering screening for NAFLD should continue to be
discussed. A recommendation for future research stemming from our work would
be to study nutritional factors that contribute to high uric acid in the US population.
High intake of sugar-sweetened soft drinks, for example, has been associated with
high uric acid levels in adults (Choi, 2008; Gao, 2007). Lastly, links between higher
dietary fructose and biopsy-proven NAFLD patients have been reported (Ouyang
et al., 2008). Fructose should be a concern in all ages, especially in children, given
the increased consumption of products containing high fructose corn syrup.
Further study of added sugars in the diet of US children and adults is needed to
elucidate the relationship between fructose intake and high levels of uric acid,
which, ultimately, can help increase awareness among people, provide evidencebased guidelines for health care providers, and provide a solid ground for change
in food policy.
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Table 1: Demographic characteristics of the study population by NAFLD status in NHANES 20012006 (n=12448)

NAFLD
n=2257
(18.1%)

Healthy
n=10191
(81.9%)

P value

Age Group (n, %)
12-19

867 (18.3%)

3847 (81.7%)

20-39

582 (19.0%)

2479 (81.0%)

40-59

494 (16.5%)

2494 (83.5%)

60-79

252 (19.3%)

1050 (80.6%)

>=80
Sex
Male (n=7195)

62 (16.2%)

321 (83.8%)

1317 (18.3%)

5878 (81.7%)

Female (n=5281)

940 (17.8%)

4341 (82.2%)

643 (18.2%)

2881 (81.8%)

913 (17.3%)

4343 (82.7%)

617 (19.4%)

2563 (80.6%)

College and above

293 (18.9%)

1256 (81.1 %)

Some College

357 (16.6%)

1796 (83.4%)

High school

366 (19.7%)

1491 (80.3%)

9-11 grade

210 (17.9%)

962 (82.1%)

< 9 grade

162 (16.3%)

831 (83.7%)

0.055

0.558

Race/ethnicity (n, %)
Mexican-Am./Other
Hisp.

0.063

Non-Hispanic white
Non-Hispanic Black
Education (n, %)
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0.052

Table 2 a: NAFLD-related risk factors in NHANES 2001-2006, age 12-19

NAFLD
(n=867)

Healthy
(n=3847)

Normal

795 (99.6%)

3491 (99.6%)

Elevated

3 (.04%)

15 (0.4%)

Normal (n, %)

695 (80.2%)

3536 (91.9%)

Elevated (n, %)

172 (19.8%)

311 (81%)

Normal

559 (65.9%)

2445 (65.5%)

Overweight

136 (16%)

594 (15.9%)

Obese
Smoking

153 (18%)

691 (18.5)

NA

NA

None

144 (16.6%)

613 (15.9%)

Below ACSM
guidelines

402 (46.4%)

1759 (38.3%)

Met ACSM
guidelines
HOMA-IR

321 (37.0%)

1475 (38.3%)

Normal

302 (80.3%)

1338 (79.6%)

P value

CRP

0.831

Uric acid
< 0.001

BMI

0.948

Never
Former

NA

Current
Physical
activity

0.746

0.752
Elevated

74 (19.7%)

343 (20.4%)
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Table 2 b: NAFLD-related risk factors in NHANES 2001-2006, age 20-39
NAFLD
n= 582

Healthy
n= 2479

P value

Normal

534 (98.9%)

2291 (98.5%)

Elevated

6 (1.1%)

34 (1.5%)

Normal

460 (79%)

2291 (92.4%)

Elevated

122 (21%)

188 (7.6%)

Normal

218 (38.7%)

1003 (41.4%)

Overweight

172 (30.5%)

755 (31.2%)

Obese
Smoking

174 (30.9%)

644 (27.4%)

Never

311 (53.5%)

1442 (58.2%)

Former

68 (11.7%)

303 (12.2%)

Current

202 (34.8)

734 (29.6%)

None

181 (31.1%)

822 (33.2%)

Below ACSM
guidelines

302 (51.9%)

1217 (491%)

99 (17%)

440 (17.7%)

Normal

211 (81.2%)

914 (82.6%)

Elevated

49 (18.8%)

193 (17.4 %)

CRP

0.531

Uric Acid

< 0.001

BMI

0.241

0.051

Physical
activity

0.473

Meeting ACSM
guidelines
HOMA-IR

23

0.592

Table 2 c: NAFLD-related risk factors in NHANES 2001-2006, age 40-59
NAFLD
n=494

Healthy
n= 2493

Normal

456 (98.1%)

2356 (98.9%)

Elevated

9 (1.9%)

26(1.1%)

Normal

383 (77.5%)

2280 (91.5%)

Elevated

111 (22.5%)

213 (8.5%)

Normal

133 (27.5%)

621 (25.6%)

Overweight

170 (35.1%)

915 (37.7%)

Obese
Smoking

181 (37.4%)

889 (36.7%)

Never

224 (45.3%)

1175 (47.2%)

Former

118 (23.9%)

303 (12.2%)

Current

152 (30.8)

734 (29.6%)

None

219 (44.3%)

1017 (40.8%)

Below ACSM
guidelines

206 (41.7%)

1112 (44.6%)

Meeting ACSM
guidelines

69 (14%)

365 (14.6%)

Normal

187 (81.7%)

811 (72.2%)

Elevated

42 (18.3%)

312 (27.8%)

P value

CRP
0.131

Uric Acid
< 0.001

BMI

0.512

0.388

Physical activity

0.339

HOMA-IR

0.003
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Table 2 d: NAFLD-related risk factors in NHANES 2001-2006, age 60-79
NAFLD
n= 252

Healthy
n= 1050

P value

Normal

242 (97.6%)

964 (97.1%)

Elevated

6 (2.4%)

29 (2.9%)

Normal

199 (79%)

978 (93.1%)

Elevated

53 (21%)

72 (6.9%)

Normal

66 (27.4%)

254 (25.3%)

Overweight

101 (41.9%)

447 (44.5%)

Obese
Smoking

74 (30.7%)

304 (30.2%)

Never

80 (31.9%)

304 (29%)

Former

123 (49%)

561 (53.5%)

Current

48 (19.1 %)

181 (17.5%)

None

121 (48%)

502 (47.8%)

Below ACSM
guidelines

28 (19%)

371 (35.3%)

Meeting ASCM
guidelines
HOMA-IR

52 (20.6%)

177 (16.9%)

Normal

92 (79.3%)

125 (67.3%)

Elevated

24 (20.7%)

161 (32.7%)

CRP
0.670

Uric Acid

< 0.001

BMI

0.725

0.443

Physical activity

0.275

0.007
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Table 2e: NAFLD-related risk factors in NHANES 2001-2006, age 80 and older
NAFLD
n= 62

Healthy
n=321

PValue

Normal

53 (100%)

296 (98%)

Elevated

0 (0%)

6 (2%)

Normal

47 (75.8%)

292 (91%)

Elevated

15 (24.2%)

29 (9%)

Normal

22 (44%)

106 (391%)

Overweight

16 (32%)

128 (47.2%)

Obese
Smoking

12 (24%)

37 (13.7%)

Never

19 (30.6%)

121 (37.9%)

Former

36 (58.1%)

183 (57.4%)

Current

7 (11.3%)

15 (4.7%)

None

39 (62.9%)

168 (52.3%)

Below ACSM

14 (22.6%)

99 (30.8%)

Meeting ACSM

9 (14.5%)

54 (16.8%)

Normal

22 (91.7%)

125 (80.6%)

Elevated

2 (8.3%)

30 (19.4%)

CRP
0.598 *

Uric Acid
0.001

BMI

0.067

0.097

Physical activity

0.295

HOMA-IR
0.258 *

*Fisher’s exact was used because there was 1 cell count expected less than 5.
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Table 3a: Metabolic syndrome components in NHANES 2001-2006 by NAFLD Status, ages 12-19
MetS component

NAFLD
n= 845

Healthy
n= 3734

P
Value

Males
Normal

416(96.1%)

1843 (95.5%)

Elevated

17 (3.9%)

78 (4.1%)

Females
Normal

393 (95.4%)

1697 (93.6%)

Elevated

19 (4.6%)

116 (6.4%)

Males
Low

77 (21.6%)

380 (23.6%)

Normal

279 (62.5%)

1227 (76.4%)

Females
Low

42 (12.5%)

207 (13.7%)

Normal

294 (87.5%)

1307 (86.3%)

Males
Normal

152 (76.4%)

686 (77.3%)

Elevated

47 (23.6%)

202 (22.7%)

Females
Normal

154 (85.6%)

638 (80.2%)

Elevated

26 (14.4%)

158 (19.8%)

Males
Normal

167 (81.9%)

728 (81.1%)

Elevated

37 (18.1%)

170 (18.9%)

Females
Normal

174 (94.1%)

742 (91.7%)

Elevated

11 (5.9%)

67 (8.3%)

WC/height ratio

0.898

0.170

HDL

0.416

0.569
Triglycerides

0.792

0.094

Fasting Glucose

0.793
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0.286

Table 3b: metabolic Syndrome Components in NHANES 2001-2006, Males 20 years and older
MetS Components
NAFLD
n=825

Healthy
n= 4283

P value

232 (58.1%)

928 (50.7%)

167 (41.9%)

904 (49.3%)

Normal

475 (57.6%)

2185 (59.3%)

Elevated

350 (42.4%)

1498 (40.7%)

Normal

261 (66.2%)

1125 (61.7%)

Elevated

133 (33.8%)

699 (38.3%)

Low

23 (30.7)

100 (27.8%)

Normal

52 (69.3%)

260 (72.2 %)

Normal

473 (62.9%)

2105 (63%)

Elevated

279 (37.1%)

1236 (37.0%)

Fasting Blood
Glucose
Normal <100 mg/dL

0.007

Elevated>=100
mg/dL
Waist
Circumference
0.335

Triglycerides

0.090

HDL

0.613

Blood pressure

0.951
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Table 3c: Metabolic Syndrome Components in NHANES 2001-2006, Females 20 years and older
MetS Component

NAFLD
n= 493

Healthy
n= 2335

Normal

181 (76.4%)

815 (75%)

Elevated

56 (23.6%)

272 (25%)

202 (41%)

970 (41.5%)

P
value

Fasting Blood Glucose

0.652

Waist Circumference
Normal

0.816
Elevated

291 (59%)

1365 (58.5%)

Normal

170 (72.6%)

824 (77.3%)

Elevated

64 (27.4%)

242 (22.7%)

Low

16 (36.4%)

89 (34.8%)

Normal

28 (63.6%)

167 (65.2%)

Normal

339 (77.9%)

1630 (80.9%)

Elevated

96 (22.1%)

384 (19.1%)

Triglycerides

0.129

HDL

0.837
Blood pressure

0.153
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Table 4: Logistic model of demographic predictors of ALT >30, age 12-19

P
predictor

OR

95% CI
value

Sex
Females (ref)
Males

0.96

(0.823-1.12)

0.6

Age

0.96

(0.93-0.99)

0.036

White

0.96

(0.8-1.16)

0.68

Black

1.2

(1.003-1.437)

0.047

0.999

(0.808-1.235)

0.953

(0.779- 1.167)

None

0.98

(0.785-1.223)

0.86

Below ACSM

0.909

(0.722-1.145)

0.42

Race/ethnicity
Hispanic (ref)

BMI
Normal (ref)
Overweight

0.99

obese
Exercise
Meeting ACSM (ref)
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Table 5: Logistic model of metabolic syndrome components as predictors of ALT>30, age 12-19

Predictor

OR

95% CI

P value

1.114

(0.79-1.57)

0.53

0.94

(0.673-1.3)

0.69

1.14

(0.82-1.61)

0.427

3.46

(2.48-4.83)

<0.001

1.038

(0.57-1.89)

0.904

0.838

(0.57-1.24)

0.377

HDL
>=40 (ref)
<40
TG
<=110 (ref)
>110
HOMA-IR
< 3.6 (ref)
>= 3.6
Uric Acid
<7 (ref)
>=7
Waist/height
ratio
<0.66 (ref)
>=0.66
Fasting glucose
<100 (ref)
>=100
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Table 6: Logistic model of demographic predictors of ALT> 30, age 20 and older

Predictor

OR

95% CI

P value

Age

0.998

(0.994-1.002)

0.266

1.103

(0,996-1.259)

0.147

None

0.943

(0.821-1.085)

0.413

Below guidelines

0.957

(0.797-1.15)

0.64

Overweight

0.935

(0.805-1.087)

0.382

Obese

1.069

(0.919-1.3)

0.384

White

0.922

(0.787-1.080)

0.254

Black

1.053

0.876-1.265)

0.584

Some college

1.32

(1.026-1.689)

0.031

High school

1.068

(0.845-1.351)

0.58

9-11 grade

1.33

(1.055-1.675)

0.016

Less than 9th grade

1.106

(0.86-1.413)

0.418

Sex
Females (ref)
Males
Physical activity
Meeting ACSM guidelines (ref)

BMI
Normal (ref)

Race/ethnicity
Hispanic (ref)

Education
College or higher (ref)
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Table 7: metabolic syndrome components and other variables as predictors of ALT>30, age 20 and
older

Predictor

OR

95% CI

P
value

Blood pressure
Normal (ref)
At risk (>130/90)

1.008

(0.812-1.25)

0.943

1.022

(0.822-1.269)

0.847

0.881

(0.708-1.094)

0.251

1.103

(0.898-1.354)

0.352

0.709

(0.54-0.932)

0.014

3.8

(2.98-4.87)

<0.001

Triglycerides
Normal (ref)
High >150
Glucose
<100 (ref)
>= 100
Waist circumference
Normal (ref)
High (>102 cm in men
and >88 cm in
women)
HOMA-IR
< 3.6 (ref)
>=3.6
Uric acid
< 7 (ref)
>= 7
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